PLGA‐Based Drug Delivery Systems: A Promising Carrier for Anti‐Diabetic Drug Delivery

Abstract Poly (lactic‐co‐glycolic acid) (PLGA) nanoparticles have emerged as a versatile platform for drug delivery due to their biodegradability, biocompatibility, and tunable release kinetics. One of the primary applications of PLGA nanoparticles in diabetes management is the encapsulation and controlled release of insulin, overcoming the limitations of frequent injections. Such systems provide sustained and stable glycemic control, reducing the risk of hypoglycaemia. Different types of PLGAs and its derivatives have been used for preparing varieties of micro/nano‐carriers to deliver insulin as well as diverse anti‐diabetic molecules, including GLP1 and its analogue (Exendin‐4),Crocetin, Metformin hydrochloride, Gliclazide, Ferulic acid, etc. to reduce hyperglycemia. This review summarizes the current state of research and development in PLGA‐based drug delivery systems for diabetes management. The review explores the various strategies employed to enhance the targeting specificity of PLGA nanoparticles in diabetes therapy. The outcome of the current review will provide an insight into the drug delivery potential and efficiency of PLGA in managing hyperglycemia and that will be useful in designing novel therapeutic to improve better control of diabetes mellitus. As research in this field continues to progress, PLGAbased systems hold great potential for revolutionizing the treatment paradigm for diabetes mellitus. This article is protected by copyright. All rights reserved